To include your compound in the COVID-19 Resource Center, submit it here.

Regulatory round-up: Array, Sandoz, Sorrento, Adello

FDA accepted for review a number of applications, including NDAs from Array BioPharma Inc. (NASDAQ:ARRY) and BLAs for two biosimilar candidates.

FDA assigned a June 30, 2018 PDUFA date to a pair of

Read the full 323 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE